Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-30T21:30:00.286Z Has data issue: false hasContentIssue false

Effects of homocysteine on metabolic pathways in cultured astrocytes

Published online by Cambridge University Press:  13 January 2009

Rights & Permissions [Opens in a new window]

Abstract

Type
Abstract
Copyright
Copyright © The Authors 2009

Homocysteine is a S-containing non-essential amino acid derived from methionine that is an important risk factor for several neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease(Reference Bell, Edman and Selhub1Reference Miller3). It plays a key role in the generation of methyl groups required for numerous biochemical reactions. Homocysteine can be either remethylated to methionine by enzymes that require folic acid, and vitamin B12 is a cofactor for this remethylation reaction, or catabolised by cystathione β-synthase, a vitamin B6-dependent enzyme, to form cysteine. There is considerable interest in the role of homocysteine in neurodegenerative diseases from a nutrition perspective, as homocysteine levels can be lowered by folic acid and vitamin B12(Reference Clarke, Smith and Jobst4, Reference Ravaglia, Forti and Maioli5).

It has been well established that increased homocysteine levels induce neuronal cell death in a variety of neuronal types(Reference Langmeier, Folbergrova and Haugvicova6). However, very few studies have probed the effects of homocysteine in astrocytes. Astrocytes closely interact with neurons to provide structural, metabolic and trophic support and actively participate in modelling neuronal excitability and neurontransmission by controlling the extracellular levels of ions and neurontransmitters(Reference Escartin, Valette and Lebon7) As a result, any modulation to astrocyte function could have potential detrimental effects on neuronal–astrocyte cross-talk(Reference Seifert, Schilling and Steinhauser8).

The present study investigated for the first time the effects of homocysteine on primary cultures of astrocytes. Primary cultures of rat astrocytes were exposed to 400 μm-homocysteine for 20 h. Metabolic extracts of cells were prepared following a 4 h incubation in minimum medium with 5.5 mm-[U-13C]glucose in the presence or absence of homocysteine. The extracts were analysed using 13C NMR. The expression level of pyruvate dehydrogenase kinase isoform 2 (PDK-2), NAD(P)H levels and mitochondrial membrane potential (ΔΨm) responses were investigated following culture in the presence of homocysteine. Metabolomic analysis was performed using 1H NMR spectroscopy and pattern recognition analysis.

PC (pyruvate carboxylase): PDH (pyruvate dehydrogenase), flux through pyruvate carboxylase:flux through pyruvate dehydrogenase; au, arbitrary units.

Following incubation with homocysteine there was a significant decrease (48%) in PC:PDH, which was the result of an increased flux through PDH. In addition, homocysteine culture resulted in a significant reduction in PDK-2 protein expression (P=0.01). Following stimulation with glucose there was a significant increase in NAD(P)H levels and impaired hyperpolarisation of the mitochondrial membrane in homocysteine-treated cells. Partial least squares discriminate analysis of the metabolic profiles showed that the most discriminating metabolites following homocysteine treatment were choline and hypotaurine. In summary, the results demonstrated that sub-lethal concentrations of homocysteine caused significant metabolic changes and altered mitochondrial function in primary cultures of astrocytes. Future studies will investigate further the detrimental effects of homocysteine on astrocytes and astrocyte–neuronal cross-talk.

References

1.Bell, IR, Edman, JS, Selhub, J et al. (1992) Acta Psychiatr Scand 86, 386390.10.1111/j.1600-0447.1992.tb03285.xCrossRefGoogle Scholar
2.Allen, RH, Stabler, SP & Lindenbaum, J (1998) Eur J Pediatr 157, Suppl. 2, S122S126.10.1007/PL00014295CrossRefGoogle Scholar
3.Miller, JW (2000) Nutrition 16, 675677.10.1016/S0899-9007(00)00307-5CrossRefGoogle Scholar
4.Clarke, R, Smith, AD, Jobst, KA et al. (1998) Arch Neurol 55, 14491455.10.1001/archneur.55.11.1449CrossRefGoogle Scholar
5.Ravaglia, G, Forti, P, Maioli, F et al. (2005) Am J Clin Nutr 82, 636643.10.1093/ajcn/82.3.636CrossRefGoogle Scholar
6.Langmeier, M, Folbergrova, J, Haugvicova, R et al. (2003) Epilepsia 44, 299304.10.1046/j.1528-1157.2003.31702.xCrossRefGoogle Scholar
7.Escartin, C, Valette, J, Lebon, V et al. (2006) J Neurochem 99, 393401.10.1111/j.1471-4159.2006.04083.xCrossRefGoogle Scholar
8.Seifert, G, Schilling, K & Steinhauser, C (2006) Nat Rev Neurosci 7, 194206.10.1038/nrn1870CrossRefGoogle Scholar